Patents

• Kinase inhibitors
• Use of PI3K inhibitors for the treatment of obesity, steatosis and ageing
• ATR inhibitors
• Use of telomerase reverse transcriptase for treatment or prevention of an age-related disorder
• Use of telomerase reverse transcriptase for treatment of conditions associated with myocardial infarction
• Protein kinase inhibitors
• Method for expanding stemness and differentiation potential of pluripotent cells
• Combined therapy against cancer
• Use of TRF1 inhibitors for the treatment or prevention of brain cancer
• Method for eliminating cancer cells
• Method for predicting the benefit of endocrine therapy in breast cancer
• Selective HASPIN inhibitors
• Use of telomerase reverse transcriptase for treatment of Dyskeratosis Congenita
• Faecal microbiota signature for pancreatic cancer

Monoclonal Antibodies

As well as suggesting new methods of classification and diagnosis, understanding the role of Monoclonal Antibodies is essential in comprehending the biology of tumour cells. The CNIO’s Monoclonal Antibodies unit produces high quality, novel antibodies. It also characterizes them, thereby allowing researchers to have dozens of reliable, validated reagents at their disposal.

Each year the CNIO publishes an in-depth catalogue highlighting the more than 80 top drawer antibodies against humans and other species currently in production.

• Monoclonal Antibodies
• CNIO mAbs catalogue (human, mouse and xenopus)
• Catalogue of monoclonal antibodies against mouse proteins

For further information on our patents and technology offerings, contact: technologytransfer@cnio.es